Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France

European Annals of Allergy and Clinical Immunology

Volumn 39, Issue 5, 2007, Pages 148-156

  Omnes, L F ^a   Bousquet, J ^b   Scheinmann, P ^c   Neukirch, F ^d   Jasso Mosqueda, G ^a   Chicoye, A ^a   Champion, L ^e   Fadel, R ^e  

^a Aremis   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d BICHAT HOSPITAL   (France)

^e Stallergenes SA   (France)

Author keywords

Allergy; Asthma; Dust mites; Pollen; Rhinitis; Specific immunotherapy; Symptomatic treatment

Indexed keywords

ALUSTAL; HOUSE DUST ALLERGEN; IMMUNOMODULATING AGENT; STALORAL; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; FOLLOW UP; FRANCE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; IMMUNOTHERAPY; PALLIATIVE THERAPY; POLLEN ALLERGY; SYMPTOM; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; ASTHMA; CHILD; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; FRANCE; HEALTH CARE COSTS; HUMANS; IMMUNOTHERAPY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 34250691985     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. International Rhinitis Management Working Group. - International consensus report on diagnosis and management of rhinitis. Allergy 1994;49(Suppl. 19):1-34.
2. Schoenwetter W.-F. - Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000;21:1-6.
3. Strachan D., Sibbald B., Weiland S. et al. - Worldwide variations in the prevalence of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161-76.
4. Aberg N., Sundell J., Eriiksson B. et al. - Prevalence of allergic diseases in schoolchildren in relation to family history, upper respiratory infections, and residential characteristics. Allergy 1996;51:232-7.
5. Sly R.-M. - Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82:233-48.
6. Gregory C., Cifaldi M., Tanner L.-A. - Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999;5:485-96.
7. Bousquet J., Bullinger M., Fayaol C. et al. - Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94:182-8.
8. Spaeth J., Klimek L., Mosges R. - Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996;51:893-906.
9. Vuurman E.-F., Van Veggel L.-M., Uiterwijk M.-M. et al. -Seasonal allergic rhinitis and antihistamine H1 effects on children's learning. Ann Allergy 1993;71:121-6.
10. Simons F.-E. - Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996;17:185-9.
11. Cockburn I.-M., Bailit H.-L., Berndt E.-T. et al. - Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999;41:948-53.
12. Malone D.-C., Lawson K.-A., Smith D.-H. et al. - A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22-7.
13. Corren J. - The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998;101:S352-6.
14. Grossman J. - One airway, one disease. Chest 1997;111(Suppl. 2):11-6.
15. Rowe-Jones J.-M. - The link between the nose and lung, perennial rhinitis and asthma - is it the same disease? Allergy 1997;52(Suppl. 36):20-28.
16. Vignola A.-M., Chanez P., Godard P. et al. - Relationships between rhinitis and asthma. Allergy 1998;53(9):833-9.
17. Townley R.-G., Kiboneka A. - Allergic rhinitis: relationship to asthma: similarities, difference and interactions. Ann Allergy Asthma Immunol 1998;80:137-9.
18. Spector S.-L. - Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997;99:773-80.
19. Yawn B.-P., Yunginger J.-W., Wollan P.-C. et al. - Allergic rhinitis in Rochester, Minesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999;317:54-9.
20. Bousquet J., Van Cauwenberge P., Khaltaev N. - Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl. 5):S147-334.
21. Ross R.-N., Nelson H.-S., Finegold I. - Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther 2000;22(3): 342-50.
22. Abramson M.-J., Puy R.-M., Weiner J.-M. - Allergen immunotherapy for asthma (Cochrane Review) In: The Cochrane Library, Chichester, UK: John Wiley & Sons Ltd, Issue 4, 2003.
23. Bousquet J., Lockey R., Malling H.-J. - Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. Allergy 1998;53(Suppl. 54).
24. Jacobsen L., Nuchel Peterson B., Wihl J.-A. et al. -Immunotherapy with partially purified and standardized tree pollen extract. Results from long-term (6 year) follow-up. Allergy 1997;52(9):914-20.
25. Durham S.-R., Walker M., Walker R.-N. et al. - Long-term clinical efficacy of grass pollen immunotherapy. N Eng J Med 1999;341(7):468-75.
26. Möller C., Dreborg S., Ferdousi H.-A. et al. - Pollen immunotherapy reduces the development of asthma in children with seasonal rhino-conjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109(2):251-6.
27. Des-Roches A., Paradis L., Ménardo J.-L. et al. -Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-3.
28. Pajno G., Barbiero G., De Luca F. et al. - Prevention of new sensitizations in asthmatic children monosensitized to house dust mites by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-7.
29. Canonica G. Passalacqua G. - Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437-48.
30. Wilson D.-R., Torres Lima M., Durham S.-R. - Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60(1):4-12.
31. Khinchi M.-S., Poulsen L.-K., Carat F. et al. - Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo controlled, double blind, double dummy study. Allergy 2004;59(1): 45-53.
32. Di Rienzo V., Marcucci F., Puccinelli P. et al. - Long lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10.
33. Global Strategy for Asthma Management and Prevention. - NIH publication. Bethesda, MD; No 02-3659 Issued January,1995 (updated 2002).
34. National Asthma Education and Prevention Program. - Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 1997. Available from http://www.nhlbi.nih.gov.
35. Serra-Batlles J., Plaza V., Morejon E. et al. - Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-6.
36. Com-Ruelle L., Grandfils N., Midy F. et al. - Les determinants du coût medical de l'asthme en Ile de France. Credes: Paris, 2002.
37. Wright A.-L., Holberg C.-J., Martinez F.-D. et al. -Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994;94:895-901.
38. Settipane G.-A., Hagy G.-W., Settipane R.-J. - Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994;15:21-5.
39. Plaschke P.-P., Janson C., Norrman E. et al. - Onset and remission of allergic rhinitis and asthma and the relationship with allergic sensitization and smoking. Am J Respir Crit Care Med 2000,162(1):920-4.
40. Guerra S., Sherrill D.-L., Martinez F.-D. et al. - Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002;109(3):419-25.
41. Berto P., Passalaqua G., Crimi N., Frati F., Ortolani C., Senna G., Canonica G.-W. - On behalf of the Italian SPAI Study Group Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy; the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol. 2006;97:615-621.
42. Simoens S. - Using the Delphi technique in economic evaluation : time to revisit the oracle ? J Clin Pharm Ther. 2006 Dec;31(6):519-22.
43. Evans C. - The use of consensus methods and experts panels in pharmacoeconomic studies. Practical applications and methodological shortcomings. Pharmacoeconomics, 2997 Aug;12(2 Pt1):121-9.
44. Schädlich P.-K., Brecht J.-G. - Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17(1):37-52.
45. Johansson G., Price M.-J., Sondhi S. - Cost effectiveness analysis of salmeterol/ fluticasone propionate 50/100 Ìg vs fluticasone propionate 100 μg in adults and adolescents with asthma. Pharmacoeconomics 1999;16(Suppl. 2):13-21.
46. Palmqvist M., Price M.-J., Sondhi S. - Cost-effectiveness analysis of salmeterol/fluticasone proprionate 50/250 Ìg vs fluticasone proprionate 250 Ìg in adults and adolescents with asthma. Pharmacoeconomics 1999;16(Suppl. 2):23-8.
47. Pieters W.-R., Lundbäk B., Sondhi S. et al. - Cost effectiveness analysis of salmeterol/fluticasone proprionate 50/500 Ìg vs fluticasone proprionate 500 μg in patients with corticosteroid-dependent asthma. Pharmacoeconomics 1999;16(Suppl. 2):29-34.
48. Barnes N.-C., Thwaites R.-M., Price M.-J. - The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med 1999;93(6):402-7.
49. Booth P.-C., Wells N.E., Morrison A.-K.- A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. Pharmacoeconomics 1996;10(3):262-8.
50. Lyseng-Williamson K.-A., Plosker G.-L. - Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003;21(13):951-89.